stockrowBioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) Book value per share
BioNTech SE Sponsored ADR's book value per share at the end of fiscal 2025 was 90.0×, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was 81.8×. Over the past ten years it has ranged from −6.6× (fiscal 2017) to 91.1× (fiscal 2023); the current reading is higher than 89% of that period. BioNTech SE Sponsored ADR ranks 8th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 90.0× | 2.99% |
| FY2024 | 87.4× | (4.06%) |
| FY2023 | 91.1× | 4.86% |
| FY2022 | 86.8× | 50.60% |
| FY2021 | 57.7× | 766.46% |
| FY2020 | 6.7× | 154.69% |
| FY2019 | 2.6× | 58.06% |
| FY2018 | 1.7× | — |
| FY2017 | −6.6× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 81.8× | 0.32% |
| Jun 2026 | 81.5× | (5.68%) |
| Mar 2026 | 86.4× | (3.98%) |
| Dec 2025 | 90.0× | (0.35%) |
| 26 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| BNTX BioNTech SE Sponsored ADR | 81.8× |
| INCY Incyte Corporation compare | 27.8× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 26.9× |
| ASND Ascendis Pharma A/S compare | 26.0× |
| GMAB Genmab A/S Sponsored ADR compare | 9.7× |
| EXEL Exelixis, Inc. compare | 7.4× |
| ROIV Roivant Sciences Ltd. compare | 6.8× |
| INSM Insmed, Inc. compare | 3.3× |
| BBIO BridgeBio Pharma, Inc. compare | −8.4× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on BNTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement